
ArriVent BioPharma fell 37.1% from $20.69 to $13.01, behind the S&P 500's +13.3%. Its worst day was Oct 6 (−47.0%), and its low came Nov 5 at $12.23.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.78 beat the $-0.86 estimate on $0.00 revenue.
−7.2% · S&P 500 −1.3%
EPS of $-0.96 missed the $-0.89 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−0.2% · S&P 500 −0.2%
ArriVent BioPharma closed at its highest level of the year, 67.9% above where the year started.
+1.1% · S&P 500 +0.8%
ArriVent BioPharma shares fell 15.0%, while the S&P 500 fell 0.2%.
−15.0% · S&P 500 −0.2%
EPS of $-1.05 missed the $-0.98 estimate on $0.00 revenue.
+0.2% · S&P 500 +0.3%
ArriVent BioPharma shares fell 47.0%, while the S&P 500 rose 0.5%.
−47.0%, the year's worst day, on 20M shares, the year's heaviest volume · S&P 500 +0.5%
ArriVent BioPharma shares fell 26.9%, while the S&P 500 rose 0.7%.
−26.9% · S&P 500 +0.7%
EPS of $-0.81 beat the $-1.06 estimate on $5.0M revenue.
−4.7% · S&P 500 −0.4%
Where it ended: a close of $13.01 on Nov 13, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-0.95, revenue est. $3.1M).
Nothing in the past 12 months.
All AVBP dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AVBP and SPY from Benzinga historical bars. Not investment advice.